Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
University of California, San Francisco
San Francisco, California
| Credit Types: | CME |
| Credit Amount: | 0.25 Credits |
| Release Date: | 2011-Jul-22 |
| Expiration Date: | 2012-Jul-21 |
| Estimated Time for Completion: | 15 minutes |
| Registration Required: | No |
| Cost: | Free |
In this activity, an expert in geriatric psychiatry addresses three key questions on the management of depression and/or anxiety in patients with dementia, management of treatment-related side effects, and treating psychosis and/or agitation in patients with dementia.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of US-based neurologists, psychiatrists, geriatricians, and primary care physicians.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: July 22, 2011 - July 21, 2012
Time to Complete: 15 minutes
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
J. Craig Nelson, MD
Professor of Psychiatry
Leon J. Epstein, MD, Endowed Chair in Geriatric Psychiatry
Director of Geriatric Psychiatry
University of California, San Francisco
San Francisco, California
J. Craig Nelson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb; Corcept Therapeutics; Covidien; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; Lundbeck, Inc.; Medtronic, Inc.; Merck & Co., Inc.; Orexigen Therapeutics, Inc.; Otsuka Pharmaceutical Co., LTD; and Pfizer Inc.
Grant/Research Support from The National Institute of Mental Health and Health Resources and Services Administration.
Honoraria from Eli Lilly and Company Global; Otsuka Pharmaceutical Co., LTD; Schering-Plough Corporation (Asia).
Shareholder in Atossa Genetics, Inc.
Advisory Board for Bristol-Myers Squibb; Eli Lilly and Company; Labopharm Inc.; and Otsuka Pharmaceutical Co., LTD.
Other Financial or Material Support from AstraZeneca; Bristol-Myers Squibb; Forest Pharmaceuticals, Inc.; and Otsuka Pharmaceutical Co., LTD in the form of industry sponsored CME programs.
James M. Smith, MD
Assistant Professor
Division of General Internal Medicine
University of Florida College of Medicine
Gainesville, Florida
James M. Smith, MD, currently has no financial interests/relationships or affiliations in relation to this activity.
Annette Wiggins
Answers in CME, Inc.
Annette Wiggins currently has no financial interests/relationships or affiliations in relation to this activity.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and Answers in CME. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly sponsored by the University of Florida College of Medicine and Answers in CME.
This activity is supported by educational grants from

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
"OpenCME has initially been made available in a "beta" edition with minimal content, functionality and online presence. Our editorial team is working hard to add many other specialty areas to the list above."
Which of the following agents has demonstrated superior efficacy in managing depression in patients with Alzheimer’s disease?
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high quality CME content by adding the OpenCME Widget to one or more of your pages.